Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Gilead

Harvoni drives growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead
 
4Q Revenues: $8.5 billion (+16%)
 
4Q Earnings: $4.7 billion (+34%)
 
FY Revenues: $32.6 billion (+31%)
 
FY Earnings: $18.1 billion (+50%)
 
Comments: Growth in the quarter was driven by Harvoni with sales of $3.3 billion, up 59%, and partially offset by Sovaldi sales ($1.5 billion, down 11%). Antiviral product sales, which include products for HIV and liver diseases, were $7.9 billion in the quarter, up 18%, primarily as a result of the launch of HCV products in Japan and continued launches across Europe, partially offset by lower sales of HCV products in the U.S. Truvada sales were $936 million in the quarter, up 4%. Atripla sales were $800 million, down 14%. Stribild sales were $511 million, up 33%. Complera / Eviplera sales were $380 million, up 9%. Viread sales were $306 million, down 2%. Letairis, Ranexa and AmBisome sales totaled $523 million in the quarter, up 5%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters